REAL-WORLD WEAR TIME IS THE KEY TO BETTER FINANCIAL OUTCOMES
Continuous glucose monitoring (CGM) is the gold standard of glycemic management¹, but low adherence rates have proven to limit its efficacy. Traditional CGM is associated with suboptimal adherence, which can lead to increased patient risk and unrecoverable costs for payers.
Almost 25% of traditional CGM spend is wasted²


About 27% of traditional CGM users discontinue use within 1 year.³

63% of traditional CGM users wear their CGM more than the clinical threshold of 70% of the time.4,5,6,7

Wear time of <70% is associated with small to no measurable A1C reduction across major randomized clinical trials.8,9
Cost of traditional CGM Nonadherence

1,000
MEMBERS START ON
TRADITIONAL CGM
376
CGM MEMBERS ARE
NONADHERENT

37.6%
Traditional CGM Member
wear time nonadherence¹⁰,¹¹,¹²,¹³

37.1%
Traditional CGM Members
wearing their sensor 70% of the time¹³,¹⁴,¹⁵,¹⁶,¹⁷

† Based on 1,000 CGM Members

OPTIMAL CGM ADHERENCE LEADS TO BETTER OUTCOMES

adherence is associated with twice the A1C reduction when compared with wear time of 41-60%.18
adherence reduces health care resource utilization, compared to traditional CGM wear time.19
- $308 PMPY less in emergency services
- $510 PMPY less in outpatient services
Eversense Reduces Patient Burden And Improves Adherence

A 90-day fully implantable sensor that simplifies daily use by eliminating self-insertions
Water-resistant* transmitter can be removed without disturbing the sensor

Gentle silicone adhesive reduces skin irritation risk18,19

Find out more on how Eversense uniquely balances performance, patient insights and a lifestyle-friendly user experience
The advanced sensor technology and under-the-skin placement help patients reach unprecedented levels of wear time, leading to improved clinical outcomes.